RxDoctor Payments Data

Francis Bayaca, MD

Family Medicine · Watsonville, CANPI 1427067768

Payments from drug & device makers

$9,230in general payments, 2019–2025

Across 490 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$912
  • Merck$791
  • Amgen$747
  • Otsuka America Pharmaceutical, Inc.$709
  • Mylan Specialty L.p.$665
  • Bayer$560
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$9,10599%
  • Education$1251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,230 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$908,309
Medicare patients
823
Services billed
12,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$113,484
OzempicSemaglutide123$111,259
ProliaDenosumab51$85,143
TrulicityDulaglutide91$76,298
MounjaroTirzepatide61$62,525
JardianceEmpagliflozin95$49,281
RybelsusSemaglutide20$44,610
RexultiBrexpiprazole28$42,322
TradjentaLinagliptin81$33,473
XareltoRivaroxaban84$28,489
Gabapentin861$27,938
JanuviaSitagliptin Phosphate50$26,101
FarxigaDapagliflozin Propanediol28$24,717
BelsomraSuvorexant104$21,343
Repatha SureclickEvolocumab20$20,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$912$155,869143 claims
Lilly USA, LLCTrulicity, Mounjaro$189$138,822152 claims
PfizerEliquis$279$113,484345 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$352$91,991194 claims
AmgenProlia$747$85,14351 claims
MerckJanuvia, Belsomra, Lagevrio (Eua)$791$61,616171 claims
Otsuka America Pharmaceutical, Inc.Rexulti$709$42,32228 claims
AstraZenecaFarxiga, Lokelma$267$36,00445 claims
GSKBreo Ellipta, Trelegy Ellipta$400$32,02857 claims
Johnson & JohnsonXarelto$230$28,48984 claims
AbbVieLinzess, Vraylar$369$25,10937 claims
Aimmune Therapeutics, Inc.Zenpep$19$12,90413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Watsonville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →